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Three junior researchers describe the hurdles 
to succeeding in the AIDS vaccine field
sSince the news in September 2007 regarding the STEP trial, the HIV research community has re-introduced basic bench science as a renewed priority, with the definition of the correlates of 
immune protection as the primary target. At the 
Summit on HIV Vaccine Research and Develop-
ment held by the National Institute of Allergy and 
Infectious Diseases last March, support for young 
investigators was deemed as a pivotal step toward 
ensuring that innovation would continue and fur-
nish the momentum and enthusiasm to move the 
AIDS vaccine field forward following the recent 
setbacks. Here we analyze the route to success for 
young investigators that are pertinent to the pres-
ent state of the field in the context of evolution.
Evolution of young investigators 
Evolution is defined as a “change in the inher-
ited traits of a population” that is achieved in at 
least three different manners: variation, reproduc-
tion, and selection. This concept is highly pertinent 
to the development of a young scientist. Based on 
the above rules for success, a young investigator 
must vary from their mentor to establish a new area 
of research in which they must learn to collaborate, 
reproduce, and develop their own lab in a location 
where they can establish their roots. They also must 
overcome both financial and creative selection
imposed by the scientific community. 
Step 1: Variation
Fundamental to the process of evolution is vari-
ation, upon which selective forces can act. A striv-
ing HIV research community is inherently a fast-
evolving organism, and as such, it requires variation 
of its own kind: new ideas, creative technology, pro-
vocative experiments, and innovative concepts. 
Support for young investigators is intended to 
build a new generation of scientists that can bring 
fresh and imaginative ideas to the field. Neverthe-
less, it is critical that we remember that youth is 
not—and has never been—a certificate of bright-
ness. However, young investigators are unique in 
that they possess the advantage of inexperience. 
Being somewhat naive affords the luxury of unorth-
odox thinking and allows one to take unusual 
approaches to addressing questions. This “naive 
curiosity” allows young investigators to extend into 
novel areas, breaking down the “walls” or bridging 
biological sciences to other domains such as math-
ematics, physics, engineering, and chemistry. These 
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spectives to the HIV research field which stem from 
the imagination of these new additions to the field.
Yet, uniqueness often can be impractical, par-
ticularly when trying to obtain funding. Novel con-
cepts are usually not immediately accepted by the 
scientific community as inherently critical and there-
fore are difficult to fund. Funding for high-risk work 
is often far more difficult to acquire than money to 
perform work in areas that are “hot” or directly 
relevant to vaccine design. However, with high risk 
can come high reward. Some of the best scientific 
publications have stemmed from research projects 
that were, at the time of inception, very high risk. It 
is also true that young scientists often lack pragma-
tism, and, as a consequence, ideas for projects that 
many consider “risky” are not lacking. However, it 
is important to appreciate the risk. While risky proj-
ects may result in high-profile papers, they also can 
become exercises in futility. A lab invested too heav-
ily in risky projects may have funding difficulties 
and young investigators being considered for tenure 
may not be favorably reviewed with multiple failed 
projects under their belts. Junior scientists must 
carefully balance risky projects, which may result in 
highly visible publications, with more secure, more 
fundable projects that can result in more guaran-
teed, albeit less high-profile, publications.
These days, young investigators can find uncon-
ventional support by interdigitating their novel pro-
grams in larger scientific networks to form symbiotic 
relationships and support their growing laborato-
ries. One model currently employed by the field is the 
use of large consortia to promote collaboration and 
advance the science efficiently, as individual collabo-
rators bring different types of expertise to a project. 
These consortia play a dominant role in scientific 
progress and therefore young investigators are being 
strongly encouraged to participate. These science 
consortia provide the critical mass that is indispens-
able to perform large-scale studies, which require 
both rich collaborative networks and expensive 
technology, and also are an integral part of many 
laboratories’ financial backing. 
Furthermore, large consortia offer support for 
the high-risk ideas of young scientists. Here are sev-
eral examples of how our work has been influenced 
by these consortia. Through the Center for HIV/
AIDS Vaccine Immunology (CHAVI), Galit Alter 
has gained visibility and been funded to perform 
high-risk work in the development of a new plat-
form to quantify antibody dependent cell-mediated 
cytoxicity (ADCC). Jacques Fellay is also working 
with CHAVI on HIV host genomic projects. The 
Ragon Institute (formerly known as Partners AIDS 
Research Center or PARC) has also begun to offer 
innovation awards that are targeted toward young 
investigators interested in initiating high-risk, “out-
of-the-box” collaborations to develop new tech-
nologies that may move the field forward. Through 
the Ragon Institute, Alter has now partnered with 
researchers at Massachusetts Institute of Technol-
ogy to develop high-tech imaging tools to gain an 
in-depth appreciation for the enigmatic role of nat-
ural killer cells in HIV infection. Thus CHAVI and 
the Ragon Institute have taken a momentous initia-
tive to encourage and provide small, catalyst-style 
grants to new investigators to support innovative 
ideas that pertain to vaccine design. 
Collaborations are also important for young 
investigators because they increase their visibility 
within their respective fields. For example, while 
working as a post-doctoral fellow Jason Brenchley 
became involved in a consortium led by Michael 
Lederman of Case Western Reserve University in 
Ohio called “The Bad Boys of Cleveland” (BBC). 
This consortium began as a small group of research-
ers interested in the role and causes of immune acti-
vation in the chronic phase of HIV infection.  These 
researchers would meet every nine months to dis-
cuss current data and plan future experiments. 
These meetings significantly increased the visibility 
of Jason Brenchley, generated many active collabo-
rations, led to five co-authored papers (one as a first 
author and one as last author), and introduced him 
to several premier researchers in the field. These 
introductions ultimately led to his being able to 
recruit a very talented post-doctoral fellow into his 
own lab. The BBC is now funded by an US National 
Institutes of Health (NIH) P01 grant and the pro-
ductive collaborations continue. 
The NIH also recently launched larger grants 
that are directly aimed at supporting young scien-
tists as they transition from their mentored to their 
independent phases, the K99/R00. These young 
investigator grants are a vital resource in the tenu-
ous period during the early career transition to 
independence. The K99/R00 has played a pivotal 
role in the early career development of Galit Alter 
and afforded her with the financial support to tran-
It is critical to remember that youth is not—and never 
has been—a certificate of brightness. However, 
young investigators are unique in that they possess
the advantage of inexperience.
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sition to independence and build her laboratory. 
With this grant, she was able to recruit a post-doc-
toral fellow and begin to engage in the development 
of a novel technological approach to defining the 
role of innate immune receptors on the evolution of 
the T-cell synapse. Similarly, CHAVI and the HIV 
Vaccine Trials Network will also offer a “track to 
independence award” targeted at young investiga-
tors interested in simian immunodeficiency virus 
(SIV) research, and will hopefully catalyze a 
renewed movement in the area of primate research, 
which is imperative. These types of awards are 
absolutely vital in providing the financial stability 
to upcoming young investigators to engage in inde-
pendent research programs that will likely flourish 
in their future lab interests. 
Step 2: Reproduction
While the role of reproduction in the evolution 
of a young investigator may not be evident, aca-
demia forms an everlasting ecosystem due to the 
cyclical processes that sustain it. Thus through 
apprenticeship, young investigators learn from their 
mentors during graduate and post-graduate work, 
after which they themselves must provide the sup-
port to grow their own generations of mentees. The 
struggle in reproduction is therefore three-fold: 
separation and survival from the mentor, finding 
young mentees to build a lab, and finding a nurtur-
ing environment in which to build a lab.
It is impossible to argue that training is not the 
most critical catalyst for success. The skills one 
learns from a mentor mold the young investigator. 
We have all been privileged to work with exception-
ally talented mentors that have certainly had an 
immeasurable impact on our development as inves-
tigators. Our greatest obstacle is then to diversify 
ourselves from these remarkable role models and to 
generate independent areas that are equally success-
ful. The pressure is on, but similar to our mentors 
who rose to the occasion when they left their impres-
sive mentors, it is clear that those that overcome this 
obstacle are the ones that have a chance to make it 
in this ultra-competitive world. 
One of the most critical resources in the scientific 
community is the mentee, both in the form of stu-
dents and post-doctoral candidates. These individu-
als form both the labor and the neural network that 
are responsible for the rapid evolution of the career 
of a young investigator. The hurdle is attracting 
these young mentees away from the established 
investigators that offer some security of success. 
However, there are certainly advantages for mentees 
who choose to conduct their training with young 
mentors, as these mentors at this early phase in their 
careers are highly involved and intensely invested in 
the success of their mentees. At this early stage in the 
career of a young investigator, the generation of 
high-quality manuscripts is absolutely vital. Whilst 
a highly invested young mentor may be attractive to 
some trainees, this problem is both a cultural hurdle 
for the academic community as well as a problem 
with advertising for young mentors who have avail-
able positions in their laboratories.
Geography is also at play in the reproduction 
process. At the crossroad between scientific expecta-
tions and life experiences, every young researcher 
will be confronted, often repeatedly, with the daunt-
ing task of deciding where to conduct research. 
Indeed, a scientist early on in their career has the 
opportunity to experience both the freedom and the 
loneliness of a migratory bird, free to roam where the 
grass is always greener. However, with independence 
comes the necessary decision of where to set roots. 
The responsibility falls more heavily on young 
investigators from developing countries. The pres-
sure to return to their homeland is much greater, 
due to the need in their nations for capacity build-
ing. Despite the luxuries in science these individu-
als may experience in developed countries, they 
face especially tough personal and societal demands 
when making the decision to stay or go back. The 
differences are innumerable, starting with scarcer 
financial support systems, less intellectual capacity, 
difficulties in obtaining reagents, less chance of up-
to-date technological equipment, etc. Despite the 
HIV research community’s clear appreciation for 
these hurdles faced by young investigators in the 
developing world, a dearth of grants are available 
for those brave enough to make the journey home. 
However, the next generation of AIDS researchers 
should not only replenish the existing army of 
experienced investigators, significantly expand the 
number of successful scientists working in develop-
ing countries.
Step 3: Selection
Selection pressures in the world of HIV research 
are not driven by chance or circumstance. They are 
clearly determined by the scientific agenda of the 
community. Thus grant review panels and journal 
reviewers are profoundly involved in determining 
the fate of a young investigator. The conundrum lies 
in the fact that a virtual agenda is defined annually 
through conferences, publications, and brain-
storming sessions that help shape the path forward. 
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Naturally, due to their exemplary track records, the 
allocation of funds to experienced investigators is 
“safe” and is believed to have a greater likelihood 
to generate high-impact publications. However, 
young investigators must compete fiercely, and as 
mentioned above, risky propositions are not always 
favored for the fledglings. Therefore new investiga-
tors must be mindful to develop programs that are 
relevant to the current interests of the community, 
and yet sufficiently novel to appeal to their peers. 
The idea that chance might play a part in the suc-
cess of a young scientist is definitely a debatable topic. 
Timeliness seems to be a recurrent success tip: should 
investigators that develop exciting new topics at a 
time when the scientific climate favors that subject be 
construed as lucky, or just clever? Fundamentally, the 
flexibility to maneuver through the scientifically rel-
evant and novel areas of research with stealth and 
success is definitely the trait that has served the most 
successful scientists well. Timing might be due to 
luck, but the art of flexibility might also lend itself to 
being able to stay at the leading edge of the field. 
As stated above, some of the best scientific pub-
lications stem from research projects that are derived 
from ideas that arose outside the domains of the pro-
verbial box. Often young researchers have not been 
in their respective fields long enough to actually 
know the confines of such a box, and many of their 
ideas therefore represent novelties in nature that, if 
successful, aid in scientific evolution. For example, 
one of the hallmarks of chronic HIV infection is 
pleiotropic activation of the immune system. While 
a post-doctoral fellow, Jason Brenchley led a project 
with the hypothesis that the damage to the gastroin-
testinal (GI) tract that occurs during acute HIV 
infection would allow microbial products to translo-
cate from the lumen of the GI tract into peripheral 
circulation. These microbial products would then be 
a cause of the immune activation. This hypothesis 
was met with some pessimism in the field, but the 
data supported the hypothesis and was ultimately 
published in a high-profile journal. This “novelty in 
nature” has subsequently been confirmed by several 
other groups and has been shown to have a role in 
AIDS dementia, failure to reconstitute CD4+ T cells 
after initiation of antiretroviral therapy, and perhaps 
atherosclerosis. Moreover, several novel therapeutic 
interventions that aim to reduce microbial product-
mediated immune activation are currently in trial. 
Future considerations
HIV research requires both long-term com-
mitment as well as a sense of urgency. Scientific 
and political leaders have made it a priority to 
build a solid “next generation” of scientists that 
can quickly contribute to the vitality of HIV 
research by bringing fresh and imaginative ideas. 
In direct response to this pressing need, the Global 
HIV Vaccine Enterprise has launched the Young 
and Early Career Investigators (YECI) Initiative to 
contribute to the development of the Enterprise’s 
2009 Scientific Strategic Plan by articulating the 
importance of young investigators as drivers of 
innovation and by proposing the structural and 
cultural changes required to engage and retain 
new scientific talent and to integrate innovative 
ideas and new technologies into HIV vaccine 
research. Co-chaired by Dan Barouch and Thumbi 
Ndung’u, the YECI Committee is comprised of 
scientific investigators from around the world who 
are age 40 or younger, or who are within 10 years 
of receiving their terminal degree or related clini-
cal training. The Enterprise’s YECI Committee 
will increase dialogue between young and estab-
lished researchers and provide innovative and con-
structive recommendations that address the chal-
lenges young investigators  face in both developed 
and developing countries. 
The main question that this committee and the 
field have to address is how do we best attract 
young researchers to the field? And what type of 
support, both financial and otherwise, is needed to 
keep young investigators involved in HIV vaccine 
research? When trying to support the next genera-
tion of scientists, we have to ask ourselves the fol-
lowing questions: How can we increase the visibil-
ity of the next generation of thinkers, provide new 
opportunities to support high-risk initiatives of 
these new minds, revolutionize the mechanism 
used to evaluate success in light of the new scien-
tific climate, and provide a support system to help 
recruit mentees for young investigators? Appropri-
ate answers to these challenges should offer bene-
fits well beyond the newest generation of HIV sci-
entists to the whole HIV research community. ?
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